TCR² Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TCR² Therapeutics Inc.
Japanese major’s profit figures for fiscal year just ended will be hit by multiple accounting decisions related to sales, pipeline and partnerships.
Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.
Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.